肿瘤细胞治疗研究
英文原题：The present and future of CAR T-cell therapy for adult B-cell ALL.
The present and future of CAR T-cell therapy for adult B-cell ALL.
靶向CD19的CAR-T 细胞疗法（CAR-T）已改变了复发/难治性（R/R）B细胞急性淋巴细胞白血病（B-ALL）的治疗格局，美国食品药品监督管理局已批准tisagenlecleucel用于儿童/年轻成人患者，brexucabtagene autoleucel用于成人患者。
靶向CD19的CAR-T 细胞疗法（CAR-T）已改变了复发/难治性（R/R）B细胞急性淋巴细胞白血病（B-ALL）的治疗管理，美国食品药品监督管理局已批准tisagenlecleucel用于儿童/年轻成人患者，以及brexucabtagene autoleucel用于成人。疗效取决于若干因素，包括疾病负荷。新兴数据表明，桥接治疗、淋巴细胞清除，以及对部分患者而言的巩固治疗，在治疗成功中发挥重要作用。此外，界定和管理包括血液毒性在内的免疫毒性副作用的策略对于安全实施至关重要。超越CD19的CAR-T设计进展代表着持续的治疗演变。总体而言，CAR-T标志着B-ALL治疗管理的范式转变，有可能改善这一历来具有挑战性的患者群体的缓解和生存。
Chimeric antigen receptor T-cell therapy (CAR-T) targeting CD19 has transformed the management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), with the US Food and Drug Administration approval of tisagenlecleucel for pediatric/young adult patients and brexucabtagene autoleucel for adults. Efficacy is contingent upon several factors including disease burden. Emerging data suggest that bridging therapy, lymphodepletion, and, for some patients, consolidation therapy have an important role in the success of treatment. Furthermore, strategies to define and manage immunotoxic side effects including hematotoxicity is critical to safe delivery. Advancements in CAR-T design beyond CD19 represent an ongoing therapeutic evolution. Overall, CAR-T signifies a paradigm shift in B-ALL management, with the potential for improved remission and survival in a historically challenging patient population.
MEMBER ACCOUNT
登录成功会直接打开下一页。
